Literature DB >> 13896635

Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.

P R GANGADHARAM, S DEVADATTA, W FOX, C N NAIR, J B SELKON.   

Abstract

A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tuberculosis in a 1-year comparison of four domiciliary chemotherapeutic regimens-three of isoniazid alone, either in moderate (HI-1 and HI-2 regimens) or in low (H regimen) dosage, and one of isoniazid in low dosage plus p-aminosalicylic acid (PAS) (PH regimen) -has recently been undertaken by the Tuberculosis Chemotherapy Centre, Madras. This paper-the third of the series-presents information on the length of time during which inhibitory concentrations of isoniazid (0.2 mug/ml or more) were maintained in the serum and on the estimated peak serum concentrations of isoniazid produced by the four regimens and relates these factors to the therapeutic effectiveness of the different regimens.THE RESULTS SUGGESTED THAT: (a) the therapeutic superiority of the PH regimen over the isoniazid-alone regimens was only in part due to the effect of PAS in enhancing the serum levels of isoniazid; (b) the therapeutic superiority of the HI-1 regimen (moderate dosage, given in one dose a day) over the HI-2 and H regimens (moderate and low dosage, respectively, given in two doses a day) was due to the higher peak serum concentration of isoniazid produced rather than to the period minimal inhibitory concentrations of isoniazid were maintained in the serum; and (c) there was a possibility that raising the peak serum concentration of isoniazid above a critical concentration of about 3 mug/ml had a greater therapeutic effect than similar proportional increases below this concentration. It also appeared that the slightly better therapeutic response observed in the slow inactivators of isoniazid than in the rapid inactivators was due to the higher peak serum concentrations of isoniazid produced; the enhanced therapeutic effect was approximately the same as would be expected from a 50% increase in isoniazid dosage.

Entities:  

Keywords:  ISONIAZID/metabolism; TUBERCULOSIS, PULMONARY/therapy

Mesh:

Substances:

Year:  1961        PMID: 13896635      PMCID: PMC2555629     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  16 in total

1.  [Comparative effects of oral and intravenous p-aminosalicylic acid on the active blood level of isoniazid].

Authors:  J GROSSET; G CANETTI; R THIBIER; J N VIVIEN; J LEPEUPLE; A SAENZ
Journal:  Rev Tuberc       Date:  1958 Feb-Mar

2.  Effect of para-aminosalicylic acid on serum isoniazid levels in man.

Authors:  W MANDEL; M L COHN; W F RUSSELL; G MIDDLEBROOK
Journal:  Proc Soc Exp Biol Med       Date:  1956-03

3.  Mode of action of isoniazid. II.

Authors:  W R BARCLAY; D KOCH-WESER; R H EBERT
Journal:  Am Rev Tuberc       Date:  1954-11

4.  One step resistance development to isoniazid and sodium-p-aminosalicylate.

Authors:  W SZYBALSKI; V BRYSON
Journal:  J Bacteriol       Date:  1953-10       Impact factor: 3.490

5.  Distribution and excretion of radioactive isoniazid in tuberculous patients.

Authors:  W R BARCLAY; R H EBERT; G V LE ROY; R W MANTHEI; L J ROTH
Journal:  J Am Med Assoc       Date:  1953-04-18

6.  Comparison of techniques for measuring the isoniazid resistance of tubercle bacilli.

Authors:  D A MITCHISON
Journal:  J Clin Pathol       Date:  1953-05       Impact factor: 3.411

7.  The action of isoniazid (isonicotinic acid hydrazide) on intracellular tubercle bacilli.

Authors:  G B MACKANESS; N SMITH
Journal:  Am Rev Tuberc       Date:  1952-08

8.  The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 3. Virulence related to pretreatment status of disease and to response to chemotherapy.

Authors:  C V RAMAKRISHNAN; A L BHATIA; W FOX; D A MITCHISON; S RADHAKRISHNA; J B SELKON; J B SELKON; T V SUBBAIAH; S VELU; J G WALLACE
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

9.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS.

Authors:  J B SELKON; W FOX; P R GANGADHARAM; K RAMACHANDRAN; C V RAMAKRISHNAN; S VELU
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

10.  Peripheral neuritis due to isoniazid.

Authors:  S DEVADATTA; P R GANGADHARAM; R H ANDREWS; W FOX; C V RAMAKRISHNAN; J B SELKON; S VELU
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

View more
  16 in total

1.  CHEMOTHERAPY OF TUBERCULOSIS: A BACTERIOLOGIST'S VIEWPOINT.

Authors:  D A MITCHISON
Journal:  Br Med J       Date:  1965-05-22

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 4.  Philip Ellman lecture. The modern management and therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Proc R Soc Med       Date:  1977-01

Review 5.  General considerations in intermittent drug therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Postgrad Med J       Date:  1971-11       Impact factor: 2.401

6.  A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis.

Authors: 
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

7.  Compliance of patients and physicians: experience and lessons from tuberculosis-II.

Authors:  W Fox
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-09

8.  Tuberculosis: who should prescribe?

Authors:  A G Wardman; S E Williams; P G Curzon; R L Page; N J Cooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-20

9.  The scope of the controlled clinical trial, illustrated by studies of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

10.  Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis.

Authors:  P R GANGADHARAM; A L BHATIA; S RADHAKRISHNA; J B SELKON
Journal:  Bull World Health Organ       Date:  1961       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.